Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5624-5630

  Larsen, R A ^a   Bauer, M ^a   Pitisuttithum, P ^b   Sanchez, A ^a   Tansuphaswadikul, S ^c   Wuthiekanun, V ^b   Peacock, S J ^b   Simpson, A J H ^b,g   Fothergill, A W ^d   Rinaldi, M G ^d   Bustamante, B ^e   Thomas, A M ^f   Altomstone, R ^a   Day, N P J ^b,g   White, N J ^b,g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Bamrasnardura Hospital   (Thailand)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^f UNIVERSITY OF NORTHERN COLORADO   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CEREBROSPINAL FLUID; COLONY FORMING UNIT; CONTROLLED STUDY; CORRELATION COEFFICIENT; CRYPTOCOCCUS NEOFORMANS; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; COLONY COUNT, MICROBIAL; CRYPTOCOCCUS NEOFORMANS; HUMANS; MENINGITIS, CRYPTOCOCCAL; MICROBIAL SENSITIVITY TESTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 81555221156     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00034-11     Document Type: Article

References (18)

1. Bicanic, T., et al. 2008. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin. Infect. Dis. 47:123-130. (Pubitemid 351920599)
2. Brouwer, A. E., et al. 2004. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363:1764-1767. (Pubitemid 38698379)
3. Cleveland, W. S. 1993. Visualizing data. Hobart, Summit, NJ.
4. Cleveland, W. S., E. Grosse, and W. M. Shyu. 1992. Local regression models, p. 309-376. In J. M. Chambers and T. Hastie (ed.), Statistical models in S. Chapman and Hall, New York, NY.
5. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts: third information supplement. CLSI document M27-S3, vol. 28. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Dannaoui, E., et al. 2006. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob. Agents Chemother. 50:2464-2470. (Pubitemid 43993187)
7. Hollander, M., and D. A. Wolfe. 1973. Nonparametric statistical methods. Wiley, New York, NY.
8. Larsen, R. A., et al. 2007. In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis. Antimicrob. Agents Chemother. 51:343-345. (Pubitemid 46047726)
9. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts, 2nd ed. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
10. Perfect, J. R., et al. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322.
11. Pfaller, M. A., M. Castanheira, S. A. Messer, G. J. Moet, and R. N. Jones. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45-50.
12. Pfaller, M. A., and W. L. Yu. 2001. Antifungal susceptibility testing. New technology and clinical applications. Infect. Dis. Clin. North Am. 15:1227-1261. (Pubitemid 33151203)
13. Pitisuttithum, P., S. Tansuphaswadikul, A. J. Simpson, P. A. Howe, and N. J. White. 2001. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J. Infect. 43:226-233. (Pubitemid 34100463)
14. Rex, J. H., et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247. (Pubitemid 127774263)
15. Robinson, P. A., et al. 1999. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 28:82-92. (Pubitemid 29246130)
16. TIBCO Software Inc. 2011. Tibco Spotfire S+ 8 for Windows. TIBCO Software Inc., Seattle, WA.
17. van der Horst, C. M., et al. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337:15-21.
18. Venables, W. N., and B. D. Ripley. 2002. Modern applied statistics with S-Plus, 4th ed. Springer-Verlag, Inc., New York, NY.